"evERA" / ML43171

Topic of Study: Breast Cancer

Sponsor: Genentech, Inc.

Principal Investigator: David A. Riseberg, M.D., 410-783-5858

Research Coordinator: Alexandra Cline, RN, 410-951-7956; Shannon Householder, RN, 410-951-7908; Sarah Orndorff, RN 410-332-9459

Coordinated Through: Institutional Research

This is a Phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of Giredestrant plus Everolimus compared with the physician's choice of endocrine therapy plus Everolimus in patients with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. (Clinicaltrials.gov ID#: NCT05306340)